Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects

Xiao-Dong Zhu; Kang-Shuai Li; Hui-Chuan Sun

doi:10.1016/j.gendis.2020.02.002

您当前的位置：

首页 >

文章列表页 >

Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects

更新时间：2022-06-24

- Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects
- Genes & Diseases Vol. 7, Issue 3, (2020)
- 作者机构：
  
  Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University,Shanghai,China,200032
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.02.002
  CLC：
- Published：2020，
  
  Published Online：1 September 2020，
扫描看全文
Xiao-Dong Zhu, Kang-Shuai Li, Hui-Chuan Sun. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. [J]. Genes & Diseases 7(3).(2020)
DOI：

Xiao-Dong Zhu, Kang-Shuai Li, Hui-Chuan Sun. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. [J]. Genes & Diseases 7(3).(2020) DOI： 10.1016/j.gendis.2020.02.002.

摘要

Abstract

Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma (HCC) is as high as 70%. However

there are no widely accepted adjuvant therapies; therefore

no treatment has been recommended by guidelines from the American Association for the Study of Liver Disease or the European Association for the Study of the Liver. All the registered trials failed to find any treatment to prolong recurrence-free survival

which is the primary outcome in most studies

including sorafenib. Some investigator-initiated studies revealed that anti-hepatitis B virus agents

interferon-α

transcatheter chemoembolization

chemokine-induced killer cells

and other treatments prolonged patient recurrence-free survival or overall survival after curative therapies. In this review

we summarize the current status of adjuvant treatments for HCC and explain the challenges associated with designing a clinical trial for adjuvant therapy. Promising new treatments being used as adjuvant therapy

especially anti-PD-1 antibodies

are also discussed.

关键词

Keywords

Adjuvant therapyAnti-PD-1 antibodyClinical trialHepatocellular carcinomaMolecular targeted therapyRecurrence-free survival

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeting angiogenesis for liver cancer: Past, present, and future

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance

Progress in hepatectomy for hepatocellular carcinoma and peri-operation management

Related Author

Zhao-You Tang

Mrinal K. Ghosh

Malini Basu

Kirat K. Ganguly

Pratyasha Ghosh

Mouli Chatterjee

Sunny Kumar

Minnatallah Al-Yozbaki

Related Institution

Department of Economics, Bethune College, University of Calcutta, Kolkata

Department of Microbiology, Dhruba Chand Halder College, University of Calcutta, Kolkata

Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), TRUE Campus, CN-6, Sector–V, Salt Lake, Kolkata 700091, Jadavpur, Kolkata

Department of Microbiology, Michael Madhusudan Memorial College, Durgapur

Jubilee Centre for Medical Research, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala

⁰